北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学临床肿瘤学院  > 胸外科  > 期刊论文
学科主题: 临床医学
题名:
A pilot study: sequential gemcitabine/cisplatin and icotinib as induction therapy for stage IIB to IIIA non-small-cell lung adenocarcinoma
作者: Lv, Chao1; Ma, Yuanyuan1; Feng, Qin2; Fang, Fang1; Bai, Hua3; Zhao, Bingtian1; Yan, Shi1; Wu, Nan1; Zheng, Qingfeng1; Li, Shaolei1; Chen, Jinfeng1; Wang, Jia1; Feng, Yuan1; Wang, Yuzhao1; Pei, Yuquan1; Fang, Jian4; Yang, Yue1
关键词: Non-small-cell lung cancer ; Sequential ; Induction chemotherapy ; EGFR mutation ; Adenocarcinoma
刊名: WORLD JOURNAL OF SURGICAL ONCOLOGY
发表日期: 2013-04-26
DOI: 10.1186/1477-7819-11-96
卷: 11
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Oncology ; Surgery
研究领域[WOS]: Oncology ; Surgery
关键词[WOS]: TYROSINE KINASE INHIBITOR ; FACTOR RECEPTOR MUTATIONS ; PHASE-III ; EGFR MUTATIONS ; CANCER ; GEFITINIB ; CISPLATIN ; TRIAL ; CARBOPLATIN ; COMBINATION
英文摘要:

Background: A phase II clinical trial previously evaluated the sequential administration of erlotinib after chemotherapy for advanced non-small-cell lung cancer (NSCLC). This current pilot study assessed the feasibility of sequential induction therapy in patients with stage IIB to IIIA NSCLC adenocarcinoma.

Methods: Patients received gemcitabine 1,250 mg/m(2) on days 1 and 8 and cisplatin 75 mg/m(2) on day 1, followed by oral icotinib (125 mg, three times a day) on days 15 to 28. A repeatcomputed tomography(CT) scan evaluated the response to the induction treatment after two 4-week cycles and eligible patients underwent surgical resection. The primary objective was to assess the objective response rate (ORR), while EGFR and KRAS mutations and mRNA and protein expression levels of ERCC1 and RRM1 were analyzed in tumor tissues and blood samples.

Results: Eleven patients, most with stage IIIA disease, completed preoperative treatment. Five patients achieved partial response according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria (ORR=45%) and six patients underwent resection. Common toxicities included neutropenia, alanine transaminase (ALT) elevation, fatigue, dry skin, rash, nausea, alopecia and anorexia. No serious complications were recorded perioperatively. Three patients had exon 19 deletions and those with EGFR mutations were more likely to achieve a clinical response (P=0.083). Furthermore, most cases who achieved a clinical response had low levels of ERCC1 expression and high levels of RRM1.

Conclusions: Two cycles of sequentially administered gemcitabine/cisplatin with icotinib as an induction treatment is a feasible and efficacious approach for stage IIB to IIIA NSCLC adenocarcinoma, which provides evidence for the further investigation of these chemotherapeutic and molecularly targeted therapies.

语种: 英语
项目资助者: Zhejiang Beta Pharma Inc.
WOS记录号: WOS:000318495600001
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/50185
Appears in Collections:北京大学临床肿瘤学院_胸外科_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: 1.Peking Univ, Canc Hosp & Inst, Dept Pathol, Key Lab Carcinogenesis & Translat Res,Minist Educ, Beijing 100142, Peoples R China
2.Peking Univ, Canc Hosp & Inst, Dept Thorac Surg 2, Key Lab Carcinogenesis & Translat Res,Minist Educ, Beijing 100142, Peoples R China
3.Peking Univ, Canc Hosp & Inst, Dept Thorac Med Oncol 1, Key Lab Carcinogenesis & Translat Res,Minist Educ, Beijing 100142, Peoples R China
4.Peking Univ, Canc Hosp & Inst, Dept Thorac Med Oncol 2, Key Lab Carcinogenesis & Translat Res,Minist Educ, Beijing 100142, Peoples R China

Recommended Citation:
Lv, Chao,Ma, Yuanyuan,Feng, Qin,et al. A pilot study: sequential gemcitabine/cisplatin and icotinib as induction therapy for stage IIB to IIIA non-small-cell lung adenocarcinoma[J]. WORLD JOURNAL OF SURGICAL ONCOLOGY,2013,11.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Lv, Chao]'s Articles
[Ma, Yuanyuan]'s Articles
[Feng, Qin]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Lv, Chao]‘s Articles
[Ma, Yuanyuan]‘s Articles
[Feng, Qin]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit
所有评论 (0)
暂无评论
 
评注功能仅针对注册用户开放,请您登录
您对该条目有什么异议,请填写以下表单,管理员会尽快联系您。
内 容:
Email:  *
单位:
验证码:   刷新
您在IR的使用过程中有什么好的想法或者建议可以反馈给我们。
标 题:
 *
内 容:
Email:  *
验证码:   刷新

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace